Head-to-head comparison
| Property | Semaglutide | VK2735 |
|---|---|---|
| Category | Weight Loss | Weight Loss |
| Legal Status | Prescription | Research Only |
| Primary Route | subcutaneous | subcutaneous |
| Half-life | ~7 days | ~7 days (estimated, subcutaneous formulation based on once-weekly dosing kinetics) |
| Mol. Weight | 4,113.58 Da | — |
| Side Effects | Nausea (39%), Vomiting, Diarrhea | Nausea (most common, dose-dependent), Vomiting, Diarrhea |
Key differences
- Mechanism: Semaglutide activates only GLP-1 receptors; VK2735 co-activates both GLP-1 and GIP receptors, with the dual mechanism expected to produce synergistic weight loss similar to the tirzepatide approach.
- Evidence maturity: Semaglutide has completed six STEP trials with over 10,000 participants, multiple FDA approvals, and years of real-world data; VK2735 has Phase 2 VENTURE data (n=176 subcutaneous, Phase 2 oral) with Phase 3 VANQUISH trials enrolling.
- Formulations: VK2735 is being developed in both subcutaneous and oral formulations; semaglutide is available as subcutaneous injection (Ozempic, Wegovy) and oral tablet (Rybelsus), though oral semaglutide requires SNAC excipient and fasting.
- Oral convenience: VK2735's oral formulation uses proprietary delivery technology without the empty-stomach requirements of oral semaglutide (Rybelsus); however, comparative convenience data from Phase 3 is not yet available.
- Early efficacy signals: VK2735 subcutaneous showed up to 14.7% weight loss at 13 weeks in Phase 2; semaglutide's STEP data showed 15-17% at 68 weeks. The VK2735 rate of weight loss at 13 weeks suggests potentially comparable or greater long-term efficacy, but extrapolation from Phase 2 is unreliable.
- Legal status: Semaglutide is FDA-approved as a prescription medication; VK2735 is investigational with no regulatory approval and is available only through clinical trials.
The verdict
Semaglutide is the proven, approved standard with the broadest clinical evidence base of any weight-loss peptide. VK2735's dual GLP-1/GIP mechanism and early Phase 2 data suggest competitive or potentially superior efficacy, consistent with the dual-agonist advantage demonstrated by tirzepatide over semaglutide. The oral VK2735 formulation is particularly noteworthy if it achieves regulatory approval without the dosing restrictions of oral semaglutide. However, VK2735 remains years from potential approval and its Phase 3 results are pending.
Frequently asked questions
It is too early to say definitively. VK2735 Phase 2 showed up to 14.7% weight loss at 13 weeks, which is a rapid rate of loss, but Phase 2 data in 176 patients cannot be reliably compared to semaglutide's Phase 3 results in over 10,000 patients over 68 weeks. Phase 3 VANQUISH data will provide a clearer picture.
Yes. VK2735 is being developed in both subcutaneous and oral formulations. The oral Phase 2 VENTURE-Oral trial showed up to 12.2% weight loss at 13 weeks. Unlike oral semaglutide (Rybelsus), VK2735 oral uses proprietary delivery technology that does not require the SNAC excipient or empty-stomach dosing.
VK2735 is developed by Viking Therapeutics, a clinical-stage biopharmaceutical company. Semaglutide is manufactured by Novo Nordisk, the world's largest peptide pharmaceutical company. Viking is significantly smaller than Novo Nordisk, which may affect manufacturing scale and market access if VK2735 is approved.
VK2735 is in Phase 3 trials (VANQUISH-1 and VANQUISH-2) as of 2026. Assuming positive results, regulatory submission and approval could follow, but no specific timeline has been confirmed. Semaglutide is available now by prescription as Ozempic, Wegovy, and Rybelsus.
Both are dual GLP-1/GIP agonists, making them mechanistically similar. VK2735 is structurally distinct from tirzepatide and is being developed by a different company. Phase 2 VK2735 data (14.7% at 13 weeks) suggests competitive efficacy with tirzepatide, but no head-to-head trial exists.